Skip to main content

Transthyretin (TTR) Amyloid Cardiomyopathy clinical trials at UCSF
2 in progress, 1 open to new patients

  • Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

    open to eligible people ages 18 years to 90 years

    Phase 3 extension study to evaluate the safety of oral daily dosing of 20 mg or 80 mg tafamidis meglumine in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy

    San Francisco, California and other locations

  • Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

    Sorry, in progress, not accepting new patients

    This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.

    San Francisco, California and other locations